From STAT’s Andrew Joseph: GSK said this morning that it would buy RAPT Therapeutics in a deal worth $2.2 billion, picking up ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene ...

Moderna announced on Wednesday it has completed its submission to the US Food and Drug Administration for full approval of its COVID-19 vaccine for people age 18 and older, and Pfizer and BioNTech ...

Americans could soon see a major increase in access to COVID-19 vaccine booster shots. On Friday, the U.S. Food and Drug Administration (FDA) announced its Vaccines and Related Biological Products ...

WASHINGTON -- Moderna submitted its application to the U.S. Food and Drug Administration for emergency use authorization of its updated COVID-19 vaccine booster for use in people age 18 and older, the ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from respiratory ...

Pfizer Inc.'s (NYSE:PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna ...

The Food and Drug Administration is delaying a decision on authorizing Moderna Inc.’s MRNA -1.69% COVID-19 vaccine for adolescents to assess whether the shot may lead to heightened risk of a rare ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...